LAS VEGAS, Nov. 21, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV) a developer of innovative drugs, announced today they received notice of the publication of its novel Alzheimer's drug (SP-04) by the United States Patent and Trademark Office ("USPTO"). The USPTO Patent Application Number is US-2006-0247248-A1 and is entitled: SIGMA-1 RECEPTOR LIGAND WITH ACETYLCHOLINESTERASE.
You may view the published application on-line after the publication date using the publication search database on the USPTO website (www.uspto.gov).
Eugene Boyle, CFO of Samaritan, and Patent Agent, stated, "We are extremely pleased to add another publication to our patent portfolio, especially for Alzheimer's. SP-04 is distinct from our lead Alzheimer's drug Caprospinol, in that it has a completely different mechanism of action, which puts us in position to have more shots on goal. The publication of the patent application means the USPTO has disclosed the invention for public review and comment of claims contained in the patent. The patent has not been 'approved' or 'issued,' therefore it still an application."
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at http://www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K/A filed November 2, 2006. The company undertakes no duty to update forward-looking statements.